Skip to main content
GOSS
NASDAQ Life Sciences

Gossamer Bio Executes 1-for-80 Reverse Split to Regain Nasdaq Compliance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$0.186
Mkt Cap
$87.944M
52W Low
$0.114
52W High
$3.87
52W Position info
63% above low
Off High info
95% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

GOSS sits 63% above its 52-week low of $0.114 on light trading volume (0.3× avg).

Summary

Gossamer Bio finalized a 1-for-80 reverse stock split to regain Nasdaq minimum bid compliance, effective September 10, 2026, with trading on a split-adjusted basis starting September 11.


Key Events · Corporate Governance and Compliance · GOSS

  • 1-for-80 Reverse Split Selected

    Board chose a 1-for-80 reverse stock split ratio, effective September 10, 2026 at 11:59 p.m. ET, with split-adjusted trading on Nasdaq beginning September 11 under new CUSIP 38341P 201.

  • Nasdaq Compliance Objective

    The reverse split is intended to help the company regain compliance with Nasdaq's minimum bid price requirement, addressing delisting risk previously disclosed in the Q2 10-Q.

  • Authorized Share Reduction

    Authorized common shares reduced from 4,000,000,000 to 50,000,000; total authorized capital stock reduced from 4,070,000,000 to 120,000,000.

  • Proportional Adjustments to Derivatives

    Conversion rates on convertible notes, warrant and prefunded warrant exercise prices, and equity award share counts will be proportionately adjusted for the 1-for-80 ratio.


Analysis · GOSS · Life Sciences

Gossamer Bio's board selected a 1-for-80 reverse stock split, effective September 10, 2026, with trading on a split-adjusted basis beginning September 11. The move is designed to lift the stock price above Nasdaq's $1.00 minimum bid requirement — a critical step given the company's going-concern warning and delisting risk disclosed in its Q2 10-Q. The split also reduces authorized common shares from 4 billion to 50 million, proportionally adjusting convertible notes, warrants, and equity awards. While the split itself does not change ownership percentages, it is a survival mechanism for a company with cash runway only into Q1 2027.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GOSS was trading at $0.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $87.9M. The 52-week trading range was $0.11 to $3.87. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GOSS - Latest Insights

GOSS
Nov 10, 2026, 4:49 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $10.15
Real-time Price: $11.17 info
Change: +$1.02 (+10%) info
Market Cap: $68.32M info
GOSS
Sep 23, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.19
Real-time Price: $11.17 info
Change: -$0.0225 (-0.20%) info
Market Cap: $68.32M info
GOSS
Sep 23, 2026, 4:01 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $11.00
Real-time Price: $11.17 info
Change: +$0.170 (+2%) info
Market Cap: $68.32M info
GOSS
Sep 16, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $10.93
Real-time Price: $11.17 info
Change: +$0.240 (+2%) info
Market Cap: $68.32M info
GOSS
Sep 11, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.1562
Real-time Price: $11.17 info
Change: Reverse Stock Split info
Market Cap: $68.32M info